Elizabeth Park, MD
Rheumatology · New York, NYNPI 1871988576
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $311 of the $451 with a category attached, or 69.0%. 4 manufacturers reported payments, led by Boehringer Ingelheim at 38.8% of the total. That places this record below the midpoint for rheumatology clinicians in NY, where the typical reported total is $1,764.
Across 8 payments — averaging $56.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$175
- Boston Scientific$137
- Novo Nordisk$125
- Fresenius Kabi USA, LLC$14
Across 1 payment — averaging $100,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$100K
What the payments were for
- Travel & lodging$14031%
- Food & beverage$31169%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $175 |
| Boston Scientific | 4 | $137 |
| Novo Nordisk | 1 | $125 |
| Fresenius Kabi USA, LLC | 1 | $14 |
How this compares
$451 in reported general payments places this provider in the 35th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 56 | $562,221 |
| Orencia ClickjectAbatacept | 33 | $186,810 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $147,062 |
| Actemra ActpenTocilizumab | 29 | $146,614 |
| Xeljanz XrTofacitinib Citrate | 24 | $138,255 |
| Taltz AutoinjectorIxekizumab | 11 | $71,327 |
| XeljanzTofacitinib Citrate | 11 | $63,950 |
| RasuvoMethotrexate/Pf | 23 | $15,983 |
| MethotrexateMethotrexate Sodium | 147 | $3,836 |
| Leflunomide | 64 | $3,176 |
| Mycophenolate Mofetil | 27 | $2,820 |
| Colchicine | 20 | $1,065 |
| Diclofenac Sodium | 29 | $945 |
| Hydroxychloroquine Sulfate | 31 | $610 |
| Allopurinol | 39 | $454 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.